The study is a clinical trial to assess the effectiveness of Vitamin B12 supplementation along with Iron Folic Acid (IFA) in combating anaemia. Adolescent anaemic girls will be randomly divided into two groups.
Group 1: IFA weekly supplementation along with Information, Education, Communication sessions
Group 2: IFA + Cyanocobalamin weekly supplementation along with Information, Education, Communication sessions
Duration of supplementation: 6 months

Start Date01 Jan 2012

Sponsor / Collaborator

Indian Council of Medical Research

[+1]

100 Clinical Results associated with Iron proteinsuccinylate

100 Translational Medicine associated with Iron proteinsuccinylate

100 Patents (Medical) associated with Iron proteinsuccinylate

Literatures (Medical) associated with Iron proteinsuccinylate

20 Mar 2024·BioMed Research International

Retracted: Changes of Serum Ferritin, Hemoglobin, and Serum Iron (SI) and Treatment Effect of Iron Proteinsuccinylate Oral Solution Combined with Vitamin A and D Drops on Children with Nutritional Iron Deficiency Anemia

Author: International, BioMed Research

[This retracts the article DOI: 10.1155/2022/2972617.].

01 Jan 2024·Biomedicine & Pharmacotherapy

Efficacy of polysaccharide iron complex in IDA rats: A comparative study with iron protein succinylate and ferrous succinate

Article

Author: Chen, Jiejun ; Lv, Zhihua ; Lv, Yinggang ; Jin, Xinyu ; Zang, Xiaoling ; Yang, Huanhuan

Iron deficiency anemia (IDA) is the most common nutrient-related health problem in the world. There is still a lack of comprehensive comparative study on the efficacies of commonly used iron supplements such as polysaccharide iron complex (PIC), iron protein succinylate (IPS) and ferrous succinate (FS) for IDA. In this study, we compared the PIC, IPS and FS efficacies in IDA rats via intragastric administration. The results showed that the three iron supplements had similar efficacies. PIC/IPS/FS at a dose of 15 mg Fe/kg/d for 10 d increased the hematological and serum biochemical parameters to 2.15/2.12/2.18 (Hb), 1.71/1.67/1.69 (RBC), 2.10/2.11/2.12 (HCT), 1.26/1.22/1.22 (MCV), all 1.34 (MCH), 1.15/1.15/1.14 (MCHC), 1.94/1.82/1.91 (SF), 9.75/9.67/9.53 (SI), and 23.30/22.68/21.64 (TS) times, and reduced TIBC to 0.42/0.43/0.44 times, compared to untreated IDA rats. PIC performed slightly better than IPS and FS in restoring MCV level. Meanwhile, the heart, spleen and kidney coefficients reduced to 67%/74%/65% (heart), all 59% (spleen) and 87%/88%/88% (kidney), and the liver coefficient increased to 116%/115%/116%, compared to untreated IDA rats. The liver iron content was found to be more affected by IDA than the spleen iron content. PIC/IPS/FS at 15 mg Fe/kg/d increased organ iron contents to 4.20/3.97/4.03 times (liver) and 1.36/1.24/1.41 times (spleen) within 10 d compared to untreated IDA rats, and PIC-H and FS were slightly better than IPS in restoring spleen iron content. The results of this study can provide useful data information for the comparison of three iron supplements, PIC, IPS and FS.

01 Jan 2023·Therapeutic Advances in Drug Safety

Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study

Article

Author: Zhang, Jing ; Wang, Yan ; Hui, Peiye ; Cao, Guangchao ; Xue, Zicheng ; Yan, Meixing ; Liu, Chang ; Zhang, Heng ; Wu, Jiyong ; Sun, Fusehng ; Li, Guohui ; Huang, Xin ; Zhang, Qianqian

Aims: To investigate the safety of oral iron therapy in pregnant women with iron-deficiency anemia (IDA) in the real world. Methods: A retrospective analysis was performed on 1792 pregnant patients with IDA who received oral iron supplements from 12 hospitals in Shandong Province from 1 April to 31 June 2021; follow-up and adverse reactions were recorded. They were divided into six groups according to the treatment drugs. Results: The overall adverse reaction rate was 15.4%, and the main adverse reaction site was the digestive system. The incidence of all kinds of oral iron adverse reactions from high to low in order: compound ferrous sulfate and folic acid tablets (21.88%); iron proteinsuccinylate oral solution (20.90%); ferrous succinate tablets (19.76%); ferrous succinate sustained-release tablets (18.00%); iron polysaccharide complex capsule (12.06%); and iron dextran oral solution (6.94%). It was found that there was a significant difference in the incidence of adverse reactions among the six drugs ( p < 0.05). Pairwise comparison showed that the incidence of adverse reactions was higher in the iron proteinsuccinylate oral solution than that in the iron polysaccharide complex capsule ( p < 0.05). There was no significant difference in the incidence of adverse reactions in different ages ( p > 0.05), but there was a significant difference in the incidence of adverse reactions in different gestational ages ( p < 0.05). In Adverse Drug Reaction (ADR) patients, the adverse reaction result of most patients is recovery or improvement, and there was no serious adverse reaction outcome such as sequela and death. Conclusion: All the adverse reactions of oral iron were mainly gastrointestinal adverse reactions, and no heavy adverse reactions were found. Iron proteinsuccinylate oral solution has a higher incidence of adverse reactions than iron polysaccharide complex capsule. The results showed that oral iron was safer for anemia patients during pregnancy.

100 Deals associated with Iron proteinsuccinylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	B03A	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia	ES	Smithkline Beecham Plc	-
Anemia	IT	Italfarmaco SpA	-
Anemia	TR	Italfarmaco SpA	-
Anemia	CO	Italfarmaco SpA	-
Anemia	CL	Bago sro	-
Anemia	GR	Italfarmaco SpA	-
Anemia	NZ	Douglas Pharmaceuticals Ltd.	-
Anemia	KR	Italfarmaco SpA	-
Anemia	AR	Bago sro	-
Anemia	ES	Bayer Schering Pharma AG	-
Anemia	BR	Italfarmaco SpA	-
Anemia	ES	CHIESI Farmaceutici SpA	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anemia	Preclinical	CZ	Italfarmaco SpA	13 Mar 1996

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Iron proteinsuccinylate

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation